A Statistical Approach for Comparative Assessment of the Effect of Smoke Exposure in In Vivo Experiments: A Case Study of an OECD 90-Day Inhalation Study Including 3R4F and 1R6F Reference Cigarettes

1. Organisation for Economic Co-operation and Development (OECD): Test No. 413: Subchronic Inhalation Toxicity: 90-Day Study; OECD Guidelines for the Testing of Chemicals, Section 4, OECD, Paris, France, 2018. DOI: 10.1787/9789264070806-en Organisation for Economic Co-operation and Development (OECD) Test No. 413: Subchronic Inhalation Toxicity: 90-Day Study; OECD Guidelines for the Testing of Chemicals, Section 4 OECD Paris, France 2018 10.1787/9789264070806-en Open DOISearch in Google Scholar

2. Belushkin, M., G. Jaccard, and A. Kondylis: Considerations for Comparative Tobacco Product Assessments Based on Smoke Constituent Yields; Regul. Toxicol. Pharmacol. 73 (2015) 105–113. DOI: 10.1016/j.yrtph.2015.06.017 BelushkinM. JaccardG. KondylisA. Considerations for Comparative Tobacco Product Assessments Based on Smoke Constituent Yields Regul. Toxicol. Pharmacol. 73 2015 105 113 10.1016/j.yrtph.2015.06.017 Open DOISearch in Google Scholar

3. Eldridge, A., T.R. Betson, M.V. Gama, and K. McAdam: Variation in Tobacco and Mainstream Smoke Toxicant Yields from Selected Commercial Cigarette Products; Regul. Toxicol. Pharmacol. 71 (2015) 409–427. DOI: 10.1016/j.yrtph.2015.01.006 EldridgeA. BetsonT.R. GamaM.V. McAdamK. Variation in Tobacco and Mainstream Smoke Toxicant Yields from Selected Commercial Cigarette Products Regul. Toxicol. Pharmacol. 71 2015 409 427 10.1016/j.yrtph.2015.01.006 Open DOISearch in Google Scholar

4. Verron, T., X. Cahours, and S. Colard: Extension of Critical Difference for Product Comparison. Application to Tobacco Products; Beitr. Tabakforsch. Int.. 28 (2019) 310–316. DOI: 10.2478/cttr-2019-0012 VerronT. CahoursX. ColardS. Extension of Critical Difference for Product Comparison. Application to Tobacco Products Beitr. Tabakforsch. Int.. 28 2019 310 316 10.2478/cttr-2019-0012 Open DOISearch in Google Scholar

5. U.S. Food and Drug Administration (FDA), Center for Tobacco Products (CTP): Guidance for Industry and FDA Staff, Section 905(j) Reports: Demonstrating Substantial Equivalence for Tobacco Products; FDA, Silverspring, MD, USA, 2011, 14 pp. Available at: https://www.federalregister.gov/documents/2011/01/06/2011-35/guidance-for-industry-and-food-and-drug-administration-staff-section-905j-reports-demonstrating U.S. Food and Drug Administration (FDA), Center for Tobacco Products (CTP) Guidance for Industry and FDA Staff, Section 905(j) Reports: Demonstrating Substantial Equivalence for Tobacco Products FDA Silverspring, MD, USA 2011 14 Available at: https://www.federalregister.gov/documents/2011/01/06/2011-35/guidance-for-industry-and-food-and-drug-administration-staff-section-905j-reports-demonstrating Search in Google Scholar

6. Dangi, Y.S., M.L. Soni, and K.P. Namdeo: Highly Variable Drugs: Bioequivalence Requirements and Regulatory Perspectives; Int. J. Curr. Pharm. Res. 3 (2010) 24–28. DangiY.S. SoniM.L. NamdeoK.P. Highly Variable Drugs: Bioequivalence Requirements and Regulatory Perspectives Int. J. Curr. Pharm. Res. 3 2010 24 28 Search in Google Scholar

7. Endrenyi, L. and L. Tothfalusi: Bioequivalence for Highly Variable Drugs: Regulatory Agreements, Disagreements, and Harmonization; J. Pharmacokinet. Pharmacodyn. 46 (2019) 117–126. DOI: 10.1007/s10928-019-09623-w EndrenyiL. TothfalusiL. Bioequivalence for Highly Variable Drugs: Regulatory Agreements, Disagreements, and Harmonization J. Pharmacokinet. Pharmacodyn. 46 2019 117 126 10.1007/s10928-019-09623-w Open DOISearch in Google Scholar

8. Endrenyi, L. and L. Tothfalusi: Regulatory and Study Conditions for the Determination of Bioequivalence of Highly Variable Drugs; J. Pharm. Pharm. Sci. 12 (2009) 138–149. DOI: 10.18433/j3zw2c EndrenyiL. TothfalusiL. Regulatory and Study Conditions for the Determination of Bioequivalence of Highly Variable Drugs J. Pharm. Pharm. Sci. 12 2009 138 149 10.18433/j3zw2c Open DOISearch in Google Scholar

9. Sakai, Y., S. Mori, M. Yanagimachi, T. Takahashi, K. Shibuya, A. Kumagai, S. Ishikawa, S. Ito, and T. Fukushima: Inter-Laboratory Reproducibility and Interchangeability of 3R4F and 1R6F Reference Cigarettes in Mainstream Smoke Chemical Analysis and In Vitro Toxicity Assays; Contrib. Tob. Nicotine Res. 29 (2020) 119–135. DOI: 10.2478/cttr-2020-0011 SakaiY. MoriS. YanagimachiM. TakahashiT. ShibuyaK. KumagaiA. IshikawaS. ItoS. FukushimaT. Inter-Laboratory Reproducibility and Interchangeability of 3R4F and 1R6F Reference Cigarettes in Mainstream Smoke Chemical Analysis and In Vitro Toxicity Assays Contrib. Tob. Nicotine Res. 29 2020 119 135 10.2478/cttr-2020-0011 Open DOISearch in Google Scholar

10. Miller, R.G.: Simultaneous Statistical Inference; Springer, New York, NY, USA, 1981, 299 pp., ISBN: 9780387905488 MillerR.G. Simultaneous Statistical Inference Springer New York, NY, USA 1981 299 9780387905488 Search in Google Scholar

11. Kim, J. and H. Bang: Three Common Misuses of P Values; Dent. Hypotheses 7 (2016) 73–80. DOI: 10.4103/2155-8213.190481 KimJ. BangH. Three Common Misuses of P Values Dent. Hypotheses 7 2016 73 80 10.4103/2155-8213.190481 Open DOISearch in Google Scholar

12. Brereton, R.G.: The Use and Misuse of P Values and Related Concepts; Chemometr. Intell. Lab. Syst. 195 (2019) 103884. DOI: 10.1016/j.chemolab.2019.103884 BreretonR.G. The Use and Misuse of P Values and Related Concepts Chemometr. Intell. Lab. Syst. 195 2019 103884 10.1016/j.chemolab.2019.103884 Open DOISearch in Google Scholar

13. Schervish, M.J.: P values: What They Are and What They Are Not; Am. Stat. 50 (1996) 203–206. DOI: 10.2307/2684655 SchervishM.J. P values: What They Are and What They Are Not Am. Stat. 50 1996 203 206 10.2307/2684655 Open DOISearch in Google Scholar

14. Wasserstein, R.L. and N. A. Lazar: The ASA Statement on p-Values: Context, Process, and Purpose; Am. Stat. 70 (2016) 129–133. DOI: 10.1080/00031305.2016.1154108 WassersteinR.L. LazarN. A. The ASA Statement on p-Values: Context, Process, and Purpose Am. Stat. 70 2016 129 133 10.1080/00031305.2016.1154108 Open DOISearch in Google Scholar

15. Anderson-Cook, C.M. and C.M. Borror: The Difference between “Equivalent” and “Not Different”; Qual. Eng. 28 (2016) 249–262. DOI: 10.1080/08982112.2015.1079918 Anderson-CookC.M. BorrorC.M. The Difference between “Equivalent” and “Not Different” Qual. Eng. 28 2016 249 262 10.1080/08982112.2015.1079918 Open DOISearch in Google Scholar

16. Barros, J.A.O.: Report on Indirect Method to Obtain Stress-Strain Response of Fiber-Reinforced Concrete (FRC); American Concrete Institute (ACI), Farmington Hills, MI, USA, 2016, 4 pp. BarrosJ.A.O. Report on Indirect Method to Obtain Stress-Strain Response of Fiber-Reinforced Concrete (FRC) American Concrete Institute (ACI) Farmington Hills, MI, USA 2016 4 Search in Google Scholar

17. U.S. Food and Drug Administration (FDA): Guidance for Industry on Statistical Approaches to Establishing Bioequivalence, Availability; FDA, Silver Spring, MD, USA, 2001, Federal Register, 66, No.23, 8805–8806. U.S. Food and Drug Administration (FDA) Guidance for Industry on Statistical Approaches to Establishing Bioequivalence, Availability FDA Silver Spring, MD, USA 2001 Federal Register, 66, No.23 8805 8806 Search in Google Scholar

18. Chow, S.C. and J.P. Liu: Recent Statistical Developments in Bioequivalence Trials - A Review of the FDA Guidance; Drug Inf. J. 28 (1994) 851–864. DOI: 10.1177/009286159402800321 ChowS.C. LiuJ.P. Recent Statistical Developments in Bioequivalence Trials - A Review of the FDA Guidance Drug Inf. J. 28 1994 851 864 10.1177/009286159402800321 Open DOISearch in Google Scholar

19. Guimarães Morais, J.A. and M. do Rosário Lobato: The New European Medicines Agency Guideline on the Investigation of Bioequivalence; Basic Clin. Pharmacol. Toxicol. 106 (2010) 221–225. DOI: 10.1111/j.1742-7843.2009.00518.x Guimarães MoraisJ.A. do Rosário LobatoM. The New European Medicines Agency Guideline on the Investigation of Bioequivalence Basic Clin. Pharmacol. Toxicol. 106 2010 221 225 10.1111/j.1742-7843.2009.00518.x Open DOISearch in Google Scholar

20. European Union: Directive 2014/40/EU of the European Parliament and of The Council of 3 April 2014 on the Approximation of the Laws, Regulations and Administrative Provisions of the Member States Concerning the Manufacture, Presentation and Sale of Tobacco and Related Products and Repealing Directive 2001/37/EC; Off. J. Eur. Union (2014) L127/1–L127/38. European Union Directive 2014/40/EU of the European Parliament and of The Council of 3 April 2014 on the Approximation of the Laws, Regulations and Administrative Provisions of the Member States Concerning the Manufacture, Presentation and Sale of Tobacco and Related Products and Repealing Directive 2001/37/EC Off. J. Eur. Union 2014 L127/1 L127/38 Search in Google Scholar

21. Schuirmann, D.J.: A Comparison of the Two One-Sided Tests Procedure and the Power Approach for Assessing the Equivalence of Average Bioavailability; J. Pharmacokinet. Biopharm. 15 (1987) 657–680. DOI: 10.1007/BF01068419 SchuirmannD.J. A Comparison of the Two One-Sided Tests Procedure and the Power Approach for Assessing the Equivalence of Average Bioavailability J. Pharmacokinet. Biopharm. 15 1987 657 680 10.1007/BF01068419 Open DOISearch in Google Scholar

22. Chow, S.-C. and J.-P. Liu: Design and Analysis of Bioavailability and Bioequivalence Studies; 1^st edition, Marcel Dekker, New York, NY, USA, 1992, 416 pp. ISBN: 9780824786823 ChowS.-C. LiuJ.-P. Design and Analysis of Bioavailability and Bioequivalence Studies 1st edition Marcel Dekker New York, NY, USA 1992 416 9780824786823 Search in Google Scholar

23. Berger, R.L. and J.C. Hsu: Bioequivalence Trials, Intersection-Union Tests and Equivalence Confidence Sets; Stat. Sci. 11 (1996) 283–319. DOI: 10.1214/ss/1032280304 BergerR.L. HsuJ.C. Bioequivalence Trials, Intersection-Union Tests and Equivalence Confidence Sets Stat. Sci. 11 1996 283 319 10.1214/ss/1032280304 Open DOISearch in Google Scholar

24. Hsu, J.C., J.T. Gene Hwang, H.K. Liu, and S.J. Ruberg: Confidence Intervals Associated with Tests for Bioequivalence; Biometrika 81 (1994) 103–114. DOI: 10.2307/2337054 HsuJ.C. Gene HwangJ.T. LiuH.K. RubergS.J. Confidence Intervals Associated with Tests for Bioequivalence Biometrika 81 1994 103 114 10.2307/2337054 Open DOISearch in Google Scholar

25. National Advisory Committee for Laboratory Animal Research (NACLAR): NACLAR Guidelines. 2004; Available at: https://www.nparks.gov.sg/avs/animals/animals-in-scientific-research/naclar-guidelines/naclar-guidelines (accessed November 2024). National Advisory Committee for Laboratory Animal Research (NACLAR) NACLAR Guidelines 2004 Available at: https://www.nparks.gov.sg/avs/animals/animals-in-scientific-research/naclar-guidelines/naclar-guidelines (accessed November 2024) Search in Google Scholar

26. National Research Council 2011. Guide for the Care and Use of Laboratory Animals: 8^th edition, The National Academies Press, Washington, DC, USA, 220 pp. DOI: 10.17226/12910 National Research Council 2011 Guide for the Care and Use of Laboratory Animals 8th edition The National Academies Press Washington, DC, USA 220 10.17226/12910 Open DOISearch in Google Scholar

27. Wong, E.T., U. Kogel, E. Veljkovic, F. Martin, Y. Xiang, S. Boue, G. Vuillaume, P. Leroy, E. Guedj, G. Rodrigo, N.V. Ivanov, J. Hoeng, M.C. Peitsch, and P. Vanscheeuwijck: Evaluation of the Tobacco Heating System 2.2. Part 4: 90-Day OECD 413 Rat Inhalation Study with Systems Toxicology Endpoints Demonstrates Reduced Exposure Effects Compared with Cigarette Smoke; Regul. Toxicol. Pharmacol. 81 Suppl 2 (2016) S59–S81. DOI: 10.1016/j.yrtph.2016.10.015 WongE.T. KogelU. VeljkovicE. MartinF. XiangY. BoueS. VuillaumeG. LeroyP. GuedjE. RodrigoG. IvanovN.V. HoengJ. PeitschM.C. VanscheeuwijckP. Evaluation of the Tobacco Heating System 2.2. Part 4: 90-Day OECD 413 Rat Inhalation Study with Systems Toxicology Endpoints Demonstrates Reduced Exposure Effects Compared with Cigarette Smoke Regul. Toxicol. Pharmacol. 81 Suppl 2 2016 S59 S81 10.1016/j.yrtph.2016.10.015 Open DOISearch in Google Scholar

28. Oviedo, A., S. Lebrun, U. Kogel, J. Ho, W.T. Tan, B. Titz, P. Leroy, G. Vuillaume, M. Bera, F. Martin, G. Rodrigo, M. Esposito, R. Dempsey, N.V. Ivanov, J. Hoeng, M.C. Peitsch, and P. Vanscheeuwijck: Evaluation of the Tobacco Heating System 2.2. Part 6: 90-Day OECD 413 Rat Inhalation Study with Systems Toxicology Endpoints Demonstrates Reduced Exposure Effects of a Mentholated Version Compared with Mentholated and Non-mentholated Cigarette Smoke; Regul. Toxicol. Pharmacol. 81 Suppl. 2 (2016) S93–S122. DOI: 10.1016/j.yrtph.2016.11.004 OviedoA. LebrunS. KogelU. HoJ. TanW.T. TitzB. LeroyP. VuillaumeG. BeraM. MartinF. RodrigoG. EspositoM. DempseyR. IvanovN.V. HoengJ. PeitschM.C. VanscheeuwijckP. Evaluation of the Tobacco Heating System 2.2. Part 6: 90-Day OECD 413 Rat Inhalation Study with Systems Toxicology Endpoints Demonstrates Reduced Exposure Effects of a Mentholated Version Compared with Mentholated and Non-mentholated Cigarette Smoke Regul. Toxicol. Pharmacol. 81 Suppl. 2 2016 S93 S122 10.1016/j.yrtph.2016.11.004 Open DOISearch in Google Scholar

29. Phillips, B.W., W.K. Schlage, B. Titz, U. Kogel, D. Sciuscio, F. Martin, P. Leroy, G. Vuillaume, S. Krishnan, T. Lee, E. Veljkovic, A. Elamin, C. Merg, N.V. Ivanov, M.C. Peitsch, J. Hoeng, and P. Vanscheeuwijck: A 90-Day OECD TG 413 Rat Inhalation Study with Systems Toxicology Endpoints Demonstrates Reduced Exposure Effects of the Aerosol from the Carbon Heated Tobacco Product version 1.2 (CHTP1.2) Compared with Cigarette Smoke. I. Inhalation Exposure, Clinical Pathology and Histopathology; Food Chem. Toxicol. 116 (2018) 388–413. DOI: 10.1016/j.fct.2018.04.015 PhillipsB.W. SchlageW.K. TitzB. KogelU. SciuscioD. MartinF. LeroyP. VuillaumeG. KrishnanS. LeeT. VeljkovicE. ElaminA. MergC. IvanovN.V. PeitschM.C. HoengJ. VanscheeuwijckP. A 90-Day OECD TG 413 Rat Inhalation Study with Systems Toxicology Endpoints Demonstrates Reduced Exposure Effects of the Aerosol from the Carbon Heated Tobacco Product version 1.2 (CHTP1.2) Compared with Cigarette Smoke. I. Inhalation Exposure, Clinical Pathology and Histopathology Food Chem. Toxicol. 116 2018 388 413 10.1016/j.fct.2018.04.015 Open DOISearch in Google Scholar

30. Jaccard, G., D.T. Djoko, A. Korneliou, R. Stabbert, M. Belushkin, and M. Esposito: Mainstream Smoke Constituents and In Vitro Toxicity Comparative Analysis of 3R4F and 1R6F Reference Cigarettes; Toxicol. Rep. 6 (2019) 222–231. DOI: 10.1016/j.toxrep.2019.02.009 JaccardG. DjokoD.T. KorneliouA. StabbertR. BelushkinM. EspositoM. Mainstream Smoke Constituents and In Vitro Toxicity Comparative Analysis of 3R4F and 1R6F Reference Cigarettes Toxicol. Rep. 6 2019 222 231 10.1016/j.toxrep.2019.02.009 Open DOISearch in Google Scholar